

DAFTAR PUSTAKA

1. Geoffrey B. Management of Diabetic Nephropathy. New York: Martin Dunitz; 2017 : 16-18
2. Hendromartono. Nefropati diabetik. Dalam: Buku ajar ilmu penyakit dalam jilid II Edisi VI. Balai penerbit FKUI: Jakarta. 2014 ; Hal 2388-96.
3. Ritz E, Keller C, Kristian H. Bergis. Nephropathy of type II diabetes melitus. Nephrol Dial Transplant (2019) 11 Suppl 9: 38-44
4. American Diabetes Association. Standart Medical Care 2017. USA. Vol. 40. Supplement; 2017. p. 1-3.
5. Wagnew F, Eshetie S, Kibret GD, Zegeye A, Dessie G, Mulugeta H, et al. Diabetic nephropathy and hypertension in diabetes patients of sub-Saharan countries: A systematic review and meta-analysis. BMC Res Notes. 2018;11(1):1–7.
6. Pearce N, Ebrahim S, McKee M, Lamprey P, Barreto ML, Matheson D, et al. Global prevention and control of NCDs: limitations of the standard approach. J Public Health Policy. 2015 Nov;36(4):408–25
7. Kim SS, Kim JH, Kim I. Current Challenges in Diabetic Nephropathy : Early Diagnostic and Way to Improve Outcomes. Endocrinol Metab 31 ; 2016; 245-253
8. Kementerian Kesehatan RI. Riset kesehatan dasar 2013 badan penelitian dan pengembangan kesehatan. Jakarta. 2013; Hal. 166 – 167.
9. Akash MSH, Rehman K, Liaqat A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Melitus. J Cell Biochem. 2018;119(1):105–10
10. Qidwai T, Khan F. Tumour Necrosis Factor Gene Polymorphism and Disease Prevalence. Scand J Immunol. 2011;74(6):522–47.
11. Alvin C. Powers. *Diabetes Melitus* in Kasper, et al editors. Harrison's The Principle of the Internal Medicine. 19th ed. United States :McGrawHill Education; 2015. Hal 2413-22

12. Kumar V., Abbas A. K., Aster, J. C., 2015 Buku Ajar Patologi Robbins. Singapura: Elsevier. Ed 9th. pp 297.
13. World Health Organization. *Global status report on non communicable diseases* 2014. WHO; 2014. (diakses 14Maret 2020) Diunduh dari URL:http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf
14. International Diabetes Federation. *Diabetes atlas* sixth edition. IDF; 2015
15. Kementerian Kesehatan RI. Riset kesehatan dasar 2013 badan penelitian dan pengembangan kesehatan. Jakarta. 2013; Hal. 166 – 167.
16. Polonsky, Kenneth S. & Charles F. *Type 2 Diabetes Melitus* in Melmed, Shlomo ; Editor. *William's textbook Endocrine*. 13th Ed. Philadelphia : Elsevier; 2016. p. 32-40.
17. American Diabetes Association. *Standart Medical Care* 2017. USA. Vol. 40. Supplement; 2017. p. 1-3.
18. Bromberg MB. Diabetic Neuropathies. In: *Peripheral Neuropathies: A Practical Approach*. Cambridge: Cambridge University Press; 2018. p. 139–43
19. Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S. Buku ajar ilmu penyakit dalam jilid II. Edisi ke-6. Jakarta: Interna Publishing; 2014. Hal 2320-98.
20. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. *N Engl J Med*. 1989;320:1161-1165.
21. Nelson RG, Morgenstern H, Bennett PH. Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians. *Diabetes*. 1998;47:1489-1493.
22. Ummanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. *Am J Kidney Dis*. 71 (6): 2018 884-895.
23. Stoimenova-Popova M, Valkova M, Veleva I, Tumbrev L, Chumpalova P, Todorov A. Diabetes melitus type 2 personality and relations with diabetic

- chronic complications—Pilot study. *European Psychiatry*. Cambridge University Press; 2017;41(S1):s507–s507
24. Hermiyanty, Wandira Ayu Bertin DS. Nefropati Diabetes. *J Chem Inf Model*. 2017;8(9):1–58
 25. Access O. A systematic review of diabetic nephropathy associated polymorphisms and its genetic model. 2019:3
 26. Arslan E, Aydın A, Demirbas S, Saglam K. Comment on “Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A.” *Nefrologia*. 2016;36(6):705.
 27. Tanabe K. VEGF-Targeting Strategies against Diabetic Nephropathy: Obsolete or Still Promising? *Biomed J Sci Tech Res*. 2018;2(3):2–4.
 28. Kim NH, Oh JH, Seo JA, Lee KW, Kim SG, Choi KM, et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. *Kidney Int*. 2005;67(1):167–77.
 29. Chen S, Ziyadeh FN. Vascular endothelial growth factor and diabetic nephropathy. *Curr Diab Rep*. 2008;8(6):470–6.
 30. Elfiani E, Nasrul E, Yanwirasti Y, Ali Z, Puspasari A. Plasma levels of the enggulfment and cell motility protein-1 are associated with kidney damage in diabetic nephropathy: A single-center pilot study in Indonesia. *Open Access Macedonin Journal of Medical Siences*. 2020 Jul 25; 8(A):418-422.
 31. Mironidou-Tzouveleki M, Tsartsalis S, Tomos C. Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus. *Curr Drug Targets*. 2010;12(1):107–14.
 32. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. *Kidney Int*. 2004;65(6):2003–17.
 33. McKnight AJ, Maxwell AP, Patterson CC, Brady HR, Savage DA. Association of VEGF-1499C→T polymorphism with diabetic nephropathy in type 1 diabetes mellitus. *J Diabetes Complications*. 2007;21(4):242–5.

34. Xie XJ, Yang YM, Jiang JK, Lu YQ. Association between the vascular endothelial growth factor single nucleotide polymorphisms and diabetic retinopathy risk: A meta-analysis. *J Diabetes*. 2017;9(8):738–53.
35. Freathy RM, Weedon MN, Shields B, Hitman GA, Walker M, McCarthy MI, et al. Functional variation in VEGF is not associated with type 2 diabetes in a United Kingdom Caucasian population. *J Pancreas*. 2006;7(3):295–302.
36. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. *Graefes Arch Clin Exp Ophthalmol*. 2009;247(1):21–6.
37. Owyong BYM, Schwartz SG, Scott IU. Cover Focus an Update on the Genetics. 2017.
38. Sun L, Yuan Q, Cao N, Guo W, Yao L, Feng JM, et al. VEGF genetic polymorphisms may contribute to the risk of diabetic nephropathy in patients with diabetes mellitus: A meta-analysis. *Sci World J*. 2014;2014.
39. Zhang L, et al. Prevalence and factors associated with CKD: a population study from Beijing. *Am J Kidney Dis*. 2018;51(3):373-84.
40. Westhuyzen J. Cystatin C: A promising marker and predictor for impaired renal function. *Ann Clin Lab Sci*. 2016; 36: 387-94.
41. Elfiani E, Halim R, Hakim MH. Hubungan antara kadar TGF-B1 dengan kadar albumin dalam urin pasien DM Tipe-2 dengan nefropati diabetik. *Jambi Medical Journal “Jurnal Kedokteran dan Kesehatan”*. 2019;7(1):73-81.
42. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. *Am J Kidney Dis*. 2012; 40: 221-6
43. Van der Meer V et al. Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice. *British Journal of General Practice*. 2010. 60: 884–90.
44. American Diabetes Association. *Standart Medical Care* 2017. USA. Vol. 40. Supplement; 2017. p. 1-3.

45. McKnight AJ, Maxwell AP, Patterson CC, Brady HR, Savage DA. Association of VEGF-1499C→T polymorphism with diabetic nephropathy in type 1 diabetes mellitus. *J Diabetes Complications*. 2007;21(4):242–5.
46. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. *Graefe's Arch Clin Exp Ophthalmol*. 2009;247(1):21–6.
47. Sun L, Yuan Q, Cao N, Guo W, Yao L, Feng JM, et al. VEGF genetic polymorphisms may contribute to the risk of diabetic nephropathy in patients with diabetes mellitus: A meta-analysis. *Sci World J*. 2014;2014.
48. Freathy RM, Weedon MN, Shields B, Hitman GA, Walker M, McCarthy MI, et al. Functional variation in VEGF is not associated with type 2 diabetes in a United Kingdom Caucasian population. *J Pancreas*. 2006;7(3):295–302
49. Tufro A, Veron D. VEGF and Podocytes in Diabetic Nephropathy. *Semin Nephrol*. 2012;32(4):385–93.
50. Iseki K. Gender differences in chronic kidney disease. *Kidney International* . 2008. 74: 415– 17